Given a paragraph, generate a claim that is supported by the given paragraph. 1) The claim must contain information from within the paragraph. 2) A sentence within the paragraph can be used as a claim. 3) The claim should not have contradictions within the paragraph. 4) The claim should be at most one sentence long.

Ex Input:
The settlements with the patient assistance charities Good Days and Patient Access Network Foundation were the first with foundations linked to an industry-wide probe that has resulted in $840 million in settlements with drugmakers. Both foundations provide assistance to patients seeking to pay out-of-pocket costs for medications. Good Days agreed to pay $2 million while PAN Foundation agreed to pay $4 million. Neither admitted wrongdoing. Good Days in a statement said the settlement will allow it to concentrate on providing help to people in need of life-saving medications. PAN said the settlement involved “legacy matters” rather than its current operations. Drug companies are prohibited from subsidizing co-payments for patients enrolled in the government’s Medicare healthcare program for those aged 65 and older. Companies may donate to non-profits providing co-pay assistance as long as they are independent. But the government has alleged that various drugmakers have used charities like Good Days and PAN as means to improperly pay the co-pay obligations of Medicare patients using their drugs, in violation of the Anti-Kickback Statute. The department said Good Days, previously known as the Chronic Disease Fund, from 2010 to 2014 conspired with companies including Novartis AG, Astellas and Questcor, now owned by Mallinckrodt Plc, to pay kickbacks to Medicare patients using their drugs. Those drugs included H.P. Acthar Gel, an expensive treatment for a rare infant seizure disorder and multiple sclerosis that is subject of a related lawsuit by the government against Mallinckrodt over Questcor’s donations to the charity. The Justice Department said Questcor from 2010 to 2014 used the charity as a conduit to improperly subsidize patients’ copays, allowing it to keep raising prices for Acthar, whose price increased from $50 per vial in 2001 to $32,200 in 2014. Mallinckrodt declined to comment. It has said it believed its actions were lawful. PAN similarly permitted Bayer AG, Astellas, Dendreon Pharmaceuticals and Amgen Inc to use it as a conduit to pay patients kickbacks, according to the government’s allegations. Astellas and Amgen in April agreed to pay $100 million and $24.75 million, respectively, to resolve related claims. Dendreon said it takes compliance seriously. Novartis declined to comment. The other companies’ representatives did not respond to requests for comment.

Ex Output:
Two charities to pay $6 million to resolve U.S. pharma kickback probe.


Ex Input:
The story says the federal government is paying about $2,250 per patient for a standard 5-day treatment course. It also notes that the approved alternative treatments are less expensive. The story points out that the benefits of peramivir have yet to be proven and that it is being offered only because some patients are not helped by approved drugs or are they are so sick they need a drug that can be given intravenously. The approved antiviral drugs are currently available only in pill or inhaled form. The story should have mentioned the side effects seen in clinical trials so far, as well as the risk that patients could suffer harms like those sometimes seen in people who have been given similar antiviral drugs. These side effects are clearly spelled out in an FDA fact sheet prepared for patients and caregivers: “The most common side effects of PERAMIVIR are: • diarrhea • nausea • vomiting • white blood cell count decreased These side effects may go away after you stop receiving PERAMIVIR. These are not all the possible side effects of PERAMIVIR. Peramivir is still being studied so it is possible that all of the risks are not known at this time. Other medicines that are used to treat people with 2009 H1N1 flu have side effects that may also happen in people who receive PERAMIVIR. These side effects include: • Signs of unusual behavior. People with the flu, especially children and adolescents, may be at a higher risk for seizures, confusion, or abnormal behavior early in their illness. These events may happen after starting PERAMIVIR or may happen if the flu is not treated. These events are not common. Patients should be watched for signs of unusual behavior. • Allergic reaction or severe rash Not a lot of people have taken PERAMIVIR for 5 days or longer. Serious and unexpected side effects may happen. The side effects of getting any medicine by vein are brief pain, bleeding, bruising of the skin where the needle enters, soreness and swelling at that spot, and possible infection at that spot.”  Patient fact sheet available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187799.pdf Provider fact sheet available at: http://www.fda.gov/downloads/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/UCM187811.pdf The story points out more than once that peramivir is still being tested and that questions remain about its potential effectiveness. The story points out that the experimental drug is being offered only to patients who are already in the hospital and aren’t being helped by approved drugs. The story did not point out that one of the supporters of faster and broader access to peramivir, Dr. Richard Whitley, has long been a booster of the drug, which is being commercially developed by a spin-off of the University of Alabama department he works in. See Whitley comments in a 2005 article promoting the potential of peramivir: http://main.uab.edu/show.asp?durki=87834 Here we also point out that the story profiled only one patient and includes a quote from the patient’s father crediting peramivir with saving his daughter’s life. The story does not give any examples of similar patients who either survived after getting approved drugs or who received peramivir and yet did not survive. Despite the clear caveats in the story, the reliance on only a single anecdote may give readers a skewed sense of the benefits of the unapproved drug. The story makes clear that the approved antiviral flu drugs are Tamiflu and Relenza. The story makes very clear that peramivir is experimental and is being offered only because some patients cannot take or aren’t helped by approved antiviral drugs. The story is quite clear that peramivir is still being tested. The story does not appear to rely on a news release.

Ex Output:
New Drug for H1N1 Flu Offers Hope


Ex Input:
Pubs, clubs and gyms have already closed, but social media on Sunday was awash with pictures of people congregating in parks and food markets, apparently ignoring advice to stay two metres apart. Parks in London are already closing down as authorities struggle to slow the advance of coronavirus through the population, the biggest public health crisis since the influenza pandemic of 1918. So far 281 Britons have died from coronavirus. The spiralling number of infections means Johnson is in a race against time to prevent a repeat of the tragedy in other countries, including Italy where the death toll reached 5,476 on Sunday. Johnson was blunt as he delivered his message to the public. “Stay two metres apart. It’s not such a difficult thing. Do it,” he said. “Otherwise.... there is going to be no doubt that we will have to bring forward further measures and we are certainly keeping that under constant review.”  Johnson said tougher measures such as curfews needed to be timed right for maximum impact. “After all, when the epidemic is hardly spreading at all that’s not the moment to impose curfews and prohibitions on movement and so on and so forth,” he said. “You’ve got to wait until, alas, it’s the right moment to do it and that’s always been how we’ve been guided.”  In another sign of the times, McDonald’s Corp (MCD.N) announced on Sunday it will temporary shut all of its more than 1,300 restaurants in Britain and Ireland by Monday evening. “This is not a decision we are taking lightly, but one made with the well-being and safety of our employees in mind as well as the best interests of our customers,” the company said in a statement on Twitter titled “See you soon.”  The latest official statistics show the number of confirmed coronavirus cases in Britain rose to 5,683 on Sunday, up from 5,018 on Saturday. Speaking alongside Johnson, communities minister Robert Jenrick said the government will write to 1.5 million of its most vulnerable citizens to demand they stay at home for the next 12 weeks to shield themselves from the virus. Senior doctors in Britain are already thinking about how they may need to ration critical care beds and ventilators if resources fall short. Johnson, who has asked British manufacturers to produce ventilators for coronavirus sufferers at short notice, said “far, far more” would be needed. Britain said on Friday that engineering companies had come up with an emergency ventilator prototype to treat coronavirus patients that could be approved next week, though one industry source told Reuters full production was several weeks away. Around 12% of adult critical care beds in hospitals in England are occupied by patients with COVID-19, England’s deputy chief medical officer, Jenny Harries, said while speaking alongside Johnson. “That will change drastically as we go through the epidemic,” she added.

Ex Output:

Johnson tells UK: Stay apart or face tougher coronavirus measures.